Back to Search Start Over

Targeting Delivery of Platelets Inhibitor to Prevent Tumor Metastasis

Authors :
Junchao Xu
Quanwei Shi
Hao Qin
Guangjun Nie
Baochang Zhao
Suping Li
Mohammad Taleb
Khosro Khajeh
Marzieh Geranpayehvaghei
Yinlong Zhang
Source :
Bioconjugate chemistry. 30(9)
Publication Year :
2019

Abstract

Activated platelets have a high affinity for tumor cells, and consequently, they can protect tumor cells from environmental stress and immune attacks. Therefore, preventing platelet-tumor cell interaction can lead to the elimination of circulating tumor cells via natural killer cells and finally metastasis inhibition. It is also shown that CREKA (Cys-Arg-Glu-Lys-Ala), a tumor-homing pentapeptide, targets fibrin-fibronectin complexes that are found on the tumor stroma and the vessel walls. In this study, we linked CREKA to Ticagrelor, a reversible antagonist of the P2Y12 receptor on platelets. In vitro experiments indicated that CREKA-Ticagrelor could not only inhibit the platelet-induced migration of tumor cells with an invasive phenotype but also prevent tumor-platelet interaction. In vivo antitumor and antimetastasis results of this drug showed that CREKA-Ticagrelor could specifically target the tumor tissues within 24 h post intravenous injection and suppress lung metastasis. Meanwhile, by having this antiplatelet drug targeted, its side effects were minimized, and bleeding risk was decreased. Thus, CREKA-Ticagrelor offers an efficient antimetastatic agent.

Details

ISSN :
15204812
Volume :
30
Issue :
9
Database :
OpenAIRE
Journal :
Bioconjugate chemistry
Accession number :
edsair.doi.dedup.....e051d541b71cd4cfc5310332581689b3